Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops

ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is being conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNFa. It is being developed initially for ophthalmic indications.

In previously reported in vivo, preclinical studies, ESBA105 achieved high therapeutic concentrations in all ocular tissues, when delivered topically via eye drops. Therapeutic concentrations of ESBA105 were observed throughout the anterior (front) and the posterior (back) segments of the eye, the latter including the vitreous humor, retina and choroid.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, commented, "ESBA105 shows an entirely novel and unique intraocular distribution pattern upon topical administration to the eye. Therapeutic levels are reached in both the aqueous and vitreous humor after only a couple of hours following initiation of treatment. Our in vivo, preclinical studies have shown that ESBA105 has a prolonged half-life of 25 hours in the vitreous. Thus, the vitreous acts as a natural depot compartment for ESBA105, allowing for highly attractive maintenance dosing regimens. TNFa is a rapidly emerging target in ophthalmology and ESBA105 has the potential to be a significant advancement in anti-inflammatory ophthalmic medicine."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "This is a major corporate milestone for ESBATech. After having developed a repeatable technol
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) today ... two upcoming investor conferences.  , 31 st ... Tuesday, December 2, 2014 at 6:45 a.m. EST / 11:45 a.m. ... EUSA International, will provide an overview of the company and a ... Jaffray Healthcare Conference in New York, NY ...
(Date:11/26/2014)... Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ("Nepstar" ... China based on the number of directly operated stores, ... quarter ended September 30, 2014. Financial HighlightsFor the ... increased by 8.1% compared to the third quarter of ... million (US$120.3 million) compared to RMB683.2 million in the third ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 10China Nepstar Chain Drugstore Ltd. Reports Third Quarter 2014 Financial Results 11
... , PALO ALTO, Calif., Oct. 14 Jazz Pharmaceuticals, Inc. ... company,s first Phase III clinical trial of sodium oxybate (JZP-6) ... during the American College of Rheumatology 2009 Annual Meeting (ACR) ... Psychiatric and Mental Health Congress (US Psych Congress) in Las ...
... Oct. 14 Pelleve(TM), a skin tightening system for ... 120 million homes across the country this weekend on ... brings consumers the latest in beauty innovation and education. ... Spaces," "Beauty Spaces" interviewed Dr. Michael Stampar to learn ...
Cached Medicine Technology:Data from Jazz Pharmaceuticals' First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences 2Data from Jazz Pharmaceuticals' First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences 3Pelleve(TM) Wrinkle Treatment System Featured On 'Beauty Spaces' TV Show 2
(Date:11/26/2014)... 2014 The family foundation of Best ... Mesothelioma Applied Research Foundation (Meso Foundation), half of which ... Patient Travel Grant Program . The focus area of ... grant partnerships with organizations that can generate transformational results ... is the founder and chairman emeritus of Best Buy ...
(Date:11/26/2014)... Claifornia (PRWEB) November 26, 2014 ... procedures which include image guided surgeries has paved ... media injectors. Rising incidence of various types of ... a proportionate increase in demand for these owing ... growth of contrast media injectors market can also ...
(Date:11/26/2014)... Arlington, VA (PRWEB) November 26, 2014 ... Ushma Suvarnakar as the Association’s new director of ... directing the Association’s annual meeting, special events and ... Ushma Suvarnakar to this post,” said AAA Executive ... contagious level of enthusiasm and energy. She was ...
(Date:11/26/2014)... Gone are the days when throngs of shoppers flood ... signifies the beginning of the Christmas shopping season. Instead, shoppers ... the comfort of their homes or on the go, away ... to be an occasion with one of the fastest growing ... in revenue for online retailers according to Adobe Digital Index. ...
(Date:11/26/2014)... For its December issue , Atlantic Information ... Blue Cross and Blue Shield Plans* interviewed officials at ... the two Blues plans are implementing in order to ... apnea, ranging from brick-and-mortar retail stores to patient data ... rates of a variety of serious disorders, including hypertension, ...
Breaking Medicine News(10 mins):Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 2Health News:Best Buy Founder’s Family Foundation Donates $100,000 to Organization Fighting Deadly Cancer 3Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:American Anthropological Association Appoints New Director of Meetings and Conferences: Ushma Suvarnakar 2Health News:2014 Best Friday Deals Revealed by Top10InAction 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3
... at the University of California, San Francisco and in ... mutations cause a number of rare human diseases, which ... The work gives doctors new possible targets for ... these diseases, which together affect perhaps one in 200 ...
... and stroke statistics collected in 192 countries by the World ... two diseases varies widely from country to country and is ... University of California, San Francisco. Reporting this week in ... developing countries tend to suffer more death and disability by ...
... (HealthDay News) -- Lace-up ankle braces may help prevent ... new study finds. The researchers looked at 1,460 male ... high schools across the United States. Some wore a lace-up ... ankle brace. During the study, acute ankle injuries occurred in ...
... By Alan Mozes HealthDay Reporter , THURSDAY, ... a torn or overstretched anterior cruciate ligament (ACL) appear to ... in their knee cartilage, new Norwegian research indicates. Such ... following an ACL injury, and these lesions can raise the ...
... "A debt ceiling agreement must be reached in time to ... patients who rely on Medicare, Medicaid and other federal health ... American College of Physicians (ACP) told the president, vice president ... our views on enactment of legislation to increase the debt ...
... a mouse genetic system co-developed by researchers at the University ... UO biologist Hui Zong has isolated the cellular origin for ... that oligodendrocyte precursor cells (OPCs) are the point of origin ... in the July 22 issue of the journal Cell ...
Cached Medicine News:Health News:UCSF team describes genetic basis of rare human diseases 2Health News:Heart disease and stroke worldwide tied to national income 2Health News:Men Seem More Likely Than Women to Develop Hole in Knee Cartilage 2Health News:Men Seem More Likely Than Women to Develop Hole in Knee Cartilage 3Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 2Health News:Debt ceiling agreement 'essential' to prevent disruption of care for Medicare & Medicaid patients 3Health News:Cellular origin of deadly brain cancer is identified 2Health News:Cellular origin of deadly brain cancer is identified 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: